Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100
Pharmaceutics · 15.11.2023 · 15 (11) · 2626
DOI: 10.3390/pharmaceutics15112626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.11.2023. Verfasst von Barbara Happl und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Vienna.
Abstract (Originalsprache)
The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic tool. Thus, this study investigated the pharmacokinetics of BOLD-100 in more detail to facilitate the stratification of patients for the therapy. The synthesis of [103Ru]BOLD-100, radiolabeled with carrier added (c.a.) ruthenium-103, was established and the product was characterized by HPLC and UV/Vis spectroscopy. In order to compare the radiolabeled and non-radioactive versions of BOLD-100, both complexes were fully evaluated in vitro and in vivo. The cytotoxicity of the compounds was determined in two colon carcinoma cell lines (HCT116 and CT26) and biodistribution studies were performed in Balb/c mice bearing CT26 allografts over a time period of 72 h post injection (p.i.). We report herein preclinical cytotoxicity and pharmacokinetic data for BOLD-100, which were found to be identical to those of its radiolabeled analog [103Ru]BOLD-100.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.
- Joint Applied Medicinal Radiochemistry Facility, University of Vienna, Medical University of Vienna, 1090 Vienna, Austria.
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland.
- Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen, Switzerland.
ORCID-Profile: Marie Brandt, Katarína Benčurová, Zeynep Talip, Petra Heffeter, Wolfgang Kandioller, Nicholas P Van der Meulen, Marcus Hacker, Thomas L Mindt
Förderung
- University of Vienna
Zitieren
APA
Happl, B., Brandt, M., Balber, T., Benčurová, K., Talip, Z., Voegele, A., Heffeter, P., Kandioller, W., Van der Meulen, N. P., Mitterhauser, M., Hacker, M., Keppler, B. K., & Mindt, T. L. (2023). Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100. Pharmaceutics, 15(11), 2626. https://doi.org/10.3390/pharmaceutics15112626
Vancouver
Happl B, Brandt M, Balber T, Benčurová K, Talip Z, Voegele A, et al. Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100. Pharmaceutics. 2023;15(11):2626. doi:10.3390/pharmaceutics15112626
BibTeX
@article{Happl2023,
author = {Happl, Barbara and Brandt, Marie and Balber, Theresa and Benčurová, Katarína and Talip, Zeynep and Voegele, Alexander and Heffeter, Petra and Kandioller, Wolfgang and Van der Meulen, Nicholas P and Mitterhauser, Markus and Hacker, Marcus and Keppler, Bernhard K and Mindt, Thomas L},
title = {Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {11},
pages = {2626},
doi = {10.3390/pharmaceutics15112626}
}
EUVIMED